0000919574-05-001355.txt : 20120622
0000919574-05-001355.hdr.sgml : 20120622
20050331134751
ACCESSION NUMBER: 0000919574-05-001355
CONFORMED SUBMISSION TYPE: SC 13G
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20050331
DATE AS OF CHANGE: 20050331
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: HOFFMAN GABE
CENTRAL INDEX KEY: 0001322420
FILING VALUES:
FORM TYPE: SC 13G
BUSINESS ADDRESS:
BUSINESS PHONE: 212-705-8700
MAIL ADDRESS:
STREET 1: C/O ACCIPITER CAPITAL MANAGEMENT, LLC
STREET 2: 399 PARK AVENUE, 37TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: INKINE PHARMACEUTICAL CO INC
CENTRAL INDEX KEY: 0000929547
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133754005
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: SC 13G
SEC ACT: 1934 Act
SEC FILE NUMBER: 005-47845
FILM NUMBER: 05718615
BUSINESS ADDRESS:
STREET 1: 1787 SENTRY PARKWAY WEST
STREET 2: BUILDING 18 SUITE 440
CITY: BLUE BELL
STATE: PA
ZIP: 19422
BUSINESS PHONE: 2152836850
MAIL ADDRESS:
STREET 1: 1787 SENTRY PARKWAY WEST
STREET 2: BUILDING 18 SUITE 440
CITY: BLUE BELL
STATE: PA
ZIP: 19422
FORMER COMPANY:
FORMER CONFORMED NAME: PANAX PHARMACEUTICAL CO LTD
DATE OF NAME CHANGE: 19940906
SC 13G
1
d559101_13g.txt
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. )
Inkine Pharmaceutical Company, Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock
--------------------------------------------------------------------------------
(Title of Class of Securities)
457214104
--------------------------------------------------------------------------------
(CUSIP Number)
February 28, 2005
--------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[_] Rule 13d-1(b)
[X] Rule 13d-1(c)
[_] Rule 13d-1(d)
CUSIP No. 457214104
---------
1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Gabe Hoffman(1)
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [_]
(b) [_]
3. SEC USE ONLY
4. CITIZENSHIP OR PLACE OF ORGANIZATION
United States of America
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
5. SOLE VOTING POWER
0
6. SHARED VOTING POWER
2,935,459
7. SOLE DISPOSITIVE POWER
0
8. SHARED DISPOSITIVE POWER
2,935,459
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,935,459
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES*
[_]
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
6.0%
12. TYPE OF REPORTING PERSON*
IN
----------
(1) The securities reported herein are held in (a) the accounts of unregistered
investment companies over which the Reporting Person has investment discretion
by virtue of the Reporting Person's positions in the general partner or
investment manager, as applicable, of said entities and (b) the Reporting
Person's personal accounts, including certain retirement accounts.
CUSIP No. 457214104
---------
Item 1(a). Name of Issuer:
Inkine Pharmaceutical Company, Inc.
--------------------------------------------------------------------
Item 1(b). Address of Issuer's Principal Executive Offices:
1787 Sentry Parkway West
Building 18
Suite 440
Blue Bell, PA 19422
--------------------------------------------------------------------
Item 2(a). Name of Person Filing:
Gabe Hoffman
--------------------------------------------------------------------
Item 2(b). Address of Principal Business Office, or if None, Residence:
c/o Accipiter Capital Management, LLC
399 Park Avenue, 37th Floor
New York, New York 10022
--------------------------------------------------------------------
Item 2(c). Citizenship:
United States of America
--------------------------------------------------------------------
Item 2(d). Title of Class of Securities:
Common Stock
--------------------------------------------------------------------
Item 2(e). CUSIP Number:
457214104
--------------------------------------------------------------------
Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or
(c), Check Whether the Person Filing is a:
(a) [_] Broker or dealer registered under Section 15 of the Exchange Act.
(b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act.
(c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange
Act.
(d) [_] Investment company registered under Section 8 of the Investment
Company Act.
(e) [_] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
(f) [_] An employee benefit plan or endowment fund in accordance with
Rule 13d-1(b)(1)(ii)(F);
(g) [_] A parent holding company or control person in accordance with
Rule 13d-1(b)(1)(ii)(G);
(h) [_] A savings association as defined in Section 3(b) of the Federal
Deposit Insurance Act;
(i) [_] A church plan that is excluded from the definition of an
investment company under Section 3(c)(14) of the Investment
Company Act;
(j) [_] Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
Item 4. Ownership.
Provide the following information regarding the aggregate number and
percentage of the class of securities of the issuer identified in Item 1.
(a) Amount beneficially owned:
2,935,459 shares
----------------------------------------------------------------------
(b) Percent of class:
6.0%
----------------------------------------------------------------------
(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote 0
------------------,
(ii) Shared power to vote or to direct the vote 2,935,459
------------------,
(iii) Sole power to dispose or to direct the
disposition of 0
------------------,
(iv) Shared power to dispose or to direct the
disposition of 2,935,459
------------------.
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial owner of more than
five percent of the class of securities check the following [ ].
N/A
----------------------------------------------------------------------
Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to
direct the receipt of dividends from, or the proceeds from the sale of, such
securities, a statement to that effect should be included in response to this
item and, if such interest relates to more than five percent of the class, such
person should be identified. A listing of the shareholders of an investment
company registered under the Investment Company Act of 1940 or the beneficiaries
of employee benefit plan, pension fund or endowment fund is not required.
N/A
----------------------------------------------------------------------
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on by the Parent Holding Company or Control
Person.
If a parent holding company or Control person has filed this schedule,
pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an
exhibit stating the identity and the Item 3 classification of the relevant
subsidiary. If a parent holding company or control person has filed this
schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating
the identification of the relevant subsidiary.
N/A
----------------------------------------------------------------------
Item 8. Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J),
so indicate under Item 3(j) and attach an exhibit stating the identity and Item
3 classification of each member of the group. If a group has filed this schedule
pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the
identity of each member of the group.
N/A
----------------------------------------------------------------------
Item 9. Notice of Dissolution of Group.
Notice of dissolution of a group may be furnished as an exhibit stating the
date of the dissolution and that all further filings with respect to
transactions in the security reported on will be filed, if required, by members
of the group, in their individual capacity. See Item 5.
N/A
----------------------------------------------------------------------
Item 10. Certification pursuant to Rule 13d-1(c):
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are not
held for the purpose of or with the effect of changing or influencing
the control of the issuer of the securities and were not acquired and
are not held in connection with or as a participant in any transaction
having such purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
March 31, 2005
----------------------------------------
(Date)
/s/ Gabe Hoffman
----------------------------------------
Gabe Hoffman
21698.0002 #559101